Sumitomo Pharma America Highlights New Clinical and Translational Research for Nuvisertib and Enzomenib at EHA 2026 Sumitomo Pharma America, Inc. (SMPA) has unveiled new clinical and translational research findings at…
Cellares Secures Additional $50 Million Investment, Expanding Series D Financing to $327 Million to Accelerate Global Cell Therapy Manufacturing Network Cellares, the world’s first Integrated Development and Manufacturing Organization (IDMO)…
Arialys Therapeutics Advances ART5803 Development With Phase 2 Progress and FDA Clearance for New Clinical Study in Anti-NMDA Receptor Encephalitis Arialys Therapeutics, a clinical-stage biotechnology company focused on developing precision…
Atara Biotherapeutics Announces Board Transition, Welcomes Veteran Investor Brian Cherry as Director Atara Biotherapeutics, Inc., a clinical-stage biotechnology company focused on advancing T-cell immunotherapies for cancer and autoimmune diseases, has…
Otsuka Completes Acquisition of Transcend Therapeutics to Advance Development of Innovative PTSD Treatment Otsuka America, Inc., a subsidiary of the global healthcare company Otsuka Pharmaceutical Co., Ltd., has completed its…
Gilead Sciences Donates More Than 2,000 Vials of Remdesivir to Support Uganda’s Ebola Bundibugyo Outbreak Response Gilead Sciences has announced the donation of more than 2,000 vials of its intravenous…
BeOne Medicines Showcases Promising Hematology Pipeline Data at EHA 2026, Highlighting Advances in BTK Degradation and Time-Limited Therapies BeOne Medicines Ltd., a global oncology company focused on developing innovative treatments…
Cepheid Donates Hemorrhagic Fever Tests to Support Ebola Outbreak Response in Democratic Republic of the Congo and Uganda Cepheid, a molecular diagnostics company and part of Danaher Corporation, has announced…
Next Health Announces Inaugural Longevity Summit in Nashville, Bringing Leading Experts Together to Explore the Future of Health and Wellness Next Health, a global company focused on health optimization, preventive…
Xeris Receives USPTO Notice of Allowance for New Patent Covering KEVEYIS®, Extending Potential Protection Through 2039 Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Biopharma Holdings, Inc., has announced a…
Zetagen Therapeutics Reports Promising Phase 2a Results for Investigational ZetaMet™ in Metastatic Breast Cancer Patients With Lytic Bone Lesions Zetagen Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative therapies…
Paragon Biosciences Completes Sale of Emalex Biosciences to Teva, Marking Another Milestone in CNS Drug Innovation Paragon Biosciences has announced the successful completion of the sale of Emalex Biosciences to…